All articles

Modern weight loss medicines are a treatment option for overweight and obesity that work by affecting the body’s biological signals related to appetite and fullness.

Overweight and obesity are influenced by complex biological, hormonal, and metabolic factors. With the right treatment, it may become easier to achieve sustainable weight loss while also reducing the risk of weight-related health conditions.

Obesity and overweight are not simply about willpower. They are influenced by the body’s biological systems that regulate hunger and fullness. GLP-1-based medicines are a modern treatment for medical weight management that can help regulate appetite, increase feelings of fullness, and support more sustainable weight loss and long-term lifestyle changes.

Mounjaro is a prescription medicine used to treat obesity and overweight. The active ingredient, tirzepatide, works by affecting the body’s biological systems involved in hunger, fullness, and blood sugar regulation, which may help reduce appetite and increase feelings of fullness.

The treatment is given as an injection once a week and is combined with lifestyle changes. In clinical studies, tirzepatide has shown good results for weight loss in people living with overweight and obesity.

Food noise involves persistent, unwanted, and tiring thoughts about food that can negatively affect quality of life. Unlike regular thoughts about food, food noise is often stressful and intrusive, revolving around hunger and cravings as well as rules, timing, and control. Food noise is a relatively new concept in research and puts into words something that many have recognized for a long time.

Weight gain after stopping GLP-1 medication is common and is partly due to appetite regulation, hunger, and energy balance gradually returning to previous levels when treatment ends. Obesity is a chronic and complex disease where biological mechanisms affect hunger, satiety, and body weight over time.

When treating with weight loss medications like Wegovy (semaglutide) and Mounjaro (tirzepatide), it is important to consider how the medications can affect fertility and the efficacy of contraceptives. Medications such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) can contribute to improved fertility in women with obesity, partly as a result of weight loss and improved hormonal and metabolic function. At the same time, they can affect the absorption and efficacy of oral contraceptives.

Losing weight with hypothyroidism can be perceived as more difficult, even with healthy lifestyle habits. An underactive thyroid means lower levels of hormones that regulate metabolism, which can affect energy expenditure and stamina. However, the effect on body weight is usually moderate and varies between individuals. When hypothyroidism is treated and hormone levels normalize, the conditions for weight loss improve.

Understanding why the body does not always respond as expected to diet and physical activity is an important starting point for the right treatment. Lipedema and overweight can in some cases resemble each other, but are two different conditions with distinct underlying mechanisms. They can also occur simultaneously, which can further complicate the clinical picture.

‍In a real-world cohort of over 40,000 people living with obesity, digital care engaged patients across all socioeconomic groups, including low- and middle-income populations. However, affordability emerged as the primary driver of treatment discontinuation, with economic barriers disproportionately limiting long-term access and continuity of care.

The demand for medical treatment of obesity and overweight has increased significantly in recent times, which in turn has contributed to the emergence of a market where medicines are sometimes distributed outside established and regulated healthcare systems. Using these medications without a doctor's prescription, and without structured and continuous follow-up, entails significant medical risks.

Sustained Real-World Weight Loss in 40,000+ Patients

Substantial weight loss was achieved with GLP-1–based pharmacotherapy within a comprehensive digital obesity care model. Outcomes were maintained up to 24 months, with 57% of patients still in treatment, demonstrating strong long-term effectiveness in real-world care.

Body Mass Index (BMI) is one of the most widely used screening tools in healthcare for estimating the relationship between body weight and height. The measurement provides a general, statistical starting point for assessing the risk of various health conditions. At the same time, it is important to emphasize that BMI has limitations and cannot alone provide a complete picture of an individual's health status on its own.

Managing overweight is rarely a matter of willpower. The body's complex biological systems interact to regulate appetite, energy expenditure, and fat storage – often in a way that counteracts weight loss. Medical weight loss aims to influence these processes and create better conditions for sustainable results over time. Here, we go through how the medications work and who the treatment is suitable for.

CagriSema is a drug treatment under development for obesity. It combines two active substances, semaglutide and cagrilintide. By integrating two hormonal mechanisms of action, the treatment aims to influence both appetite regulation and glucose metabolism more comprehensively than treatment with a single substance.

Interest in new drug treatments for obesity has increased markedly in recent years. MariTide is a treatment under clinical development that could potentially contribute to an increased understanding of the body's weight regulation and broaden treatment options for obesity.

Learn how to eat nutritiously and save money with evidence-based tips from our dietitians. Discover how weight loss medication impacts your food budget and start your journey today.

KwikPen is a pre-filled multi-dose pen from the pharmaceutical company Eli Lilly, used to administer the medication Mounjaro. This type of pen is designed to facilitate regular dosing during medical weight loss and the treatment of type 2 diabetes. Here we go through how to handle the pen safely – from preparation to correct storage – to ensure your treatment works optimally.

A protein-rich salmon bowl is a nutrient-dense meal that can actively support your weight loss by keeping you full, stabilising blood sugar, and preserving your vital muscle mass. By combining omega-3-rich salmon with fibre-rich vegetables, edamame beans, and whole grains, you create a balanced bowl that is both nutrient-dense and protein-rich. This guide explains exactly why these ingredients are optimal for your health, how to prepare the meal effectively for the week's lunch boxes, and the profound benefits the dish provides for your body.

‍

Orforglipron is an oral (non-peptide) GLP-1 receptor agonist that was recently approved in the USA (under the name Foundayo) for the treatment of adults with obesity or overweight with at least one weight-related comorbidity. In clinical studies, the treatment has shown efficacy in both weight loss and blood sugar control.

The choice between bariatric surgery and medical treatment has changed alongside the development of new, effective medications. Today, modern GLP-1 and GLP-1/GIP receptor agonists can provide significant weight loss that, in some cases, approaches the results previously achieved primarily through bariatric surgery. Here, we look at both options from a medical perspective and describe their effects, risks, and benefits.

Not losing weight despite feeling like you are doing "everything right" is rarely due to a lack of discipline. The body's biology and hormonal systems play a central role in regulating body weight and can counteract weight loss.

To achieve sustainable results, it can therefore be valuable to understand how appetite regulation and individual circumstances affect weight, as well as which evidence-based treatment options are available.

Semaglutide and tirzepatide are both well-documented medications for medical weight loss. In clinical studies, tirzepatide has shown a greater average weight loss than semaglutide, but individual efficacy, tolerability, and treatment choices vary. The choice of treatment should always be based on an individual medical assessment.

New data proves sustainable weight loss delivers significant savings for patients.

‍
A pan-European survey of 1,350+ Yazen patients reveals a "health dividend" where effective obesity treatment offsets its own cost. By addressing biological cravings, patients save an average of €109 on food and €50 on healthcare monthly. Findings show a natural shift away from snacks and takeaways toward nutrient-dense, mindful consumption.

The concept of the “Golden dose” for Mounjaro refers to the residual liquid that may remain in a KwikPen after the intended doses. Advice on using this as an extra dose is spreading on social media, but healthcare providers advise against it because the dose is not quality-assured. Extracting residual liquid can lead to incorrect dosing and increased risk of side effects. Changes in how the medication is provided aim to strengthen patient safety.